top of page
CONNECT
Let science do the talking
HOME
SCIENCE
Immune Oncology
Acetate Metabolism
Runaway Immune Response
Vaccine Adjuvants
Neuroscience
RESEARCH
Current Programs
Pipeline
Academic Alliances
Licensing & Partnership
Our Publications
TEAM
Leadership
Advisors
NEWSROOM
CSR
CAREERS
CONTACT US
More
Use tab to navigate through the menu items.
O
ur
P
ipeline
Indication Target Mode of Action
Lead Generation
Feasibility
Candidate Selection
IND Enabling
Oncology
STING
Agonist
IND enabling
Inflammation
STING
Antagonist
Lead Generation stage
Oncology
ACSS2
Inhibitor
Candidate Selection stage
Oncology
TDO/IDO
Inhibitor
IND enabling stage
Oncology
HPK1
Inhibitor
Lead Generation stage
Lead Generation stage
bottom of page
